secwatch.observer — SEC 8-K summary
======================================

Issuer:     Poseida Therapeutics, Inc. (—)
CIK:        0001661460
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001193125-24-126509
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Poseida & Astellas/Xyphos enter allogeneic CAR-T collaboration; $50M upfront, $550M milestones
--------------------------------------------------------------------------------

- $50M upfront payment ($6M advanced for R&D); up to $550M in development/sales milestones plus low double-digit tiered royalties.
- Two allogeneic convertible CAR-T candidates targeting solid tumors combining Poseida’s platform with Xyphos’ ACCEL technology.
- Xyphos responsible for development/commercialization; Poseida performs research through IND-enabling data package.
- Expands existing relationship; Astellas made strategic investment in Poseida in August 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/0001193125-24-126509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/d813637d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-126509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer